Overview
- Eli Lilly broke ground Monday on a 236‑acre Generation Park campus and has begun construction on a multi‑building site that state filings say will be completed in November 2027.
- The company estimates the project will support about 4,000 construction jobs and roughly 615 permanent positions including engineers, lab technicians and operations staff.
- The Houston plant is planned to make Foundayo, Lilly’s oral GLP-1 pill approved by the FDA in April 2026, and it will be capable of producing other small‑molecule medicines and advanced therapeutics.
- Texas approved incentives for the project that include $146 million in tax credits and a $5.5 million grant, and Lilly pledged $12.5 million for San Jacinto College training plus $2.5 million in scholarships.
- The investment follows other large life‑sciences moves in Generation Park and reflects a wider trend of reshoring active pharmaceutical ingredient production that could boost regional manufacturing capacity and supply‑chain security.